On June 8, a company's IPO application was canceled. , according to the arrangement of the SFC on June 7, the original two companies starting application for review, but on the day before going, the SFC announcement said that given the poinsettia pharmaceutical co., LTD. Are now related issues need to be further implemented, decided to cancel the 47th gem issuance examination committee meeting to report the company issuing the documents review. 

 

As a result, the CSRC has cancelled the review of the initial applications for seven companies this year. Also yesterday, Beijing pinn technology co., LTD., became the 30th company to apply for an IPO this year. 

 

According to poinsettia pharmaceutical previously disclosed in the prospectus, the company in the shenzhen stock exchange publicly issued no more than 40 million shares, issued after the total equity of not more than 160 million shares. The funds raised by a IPO plan to guangzhou embellish lam factory production base construction, research and development center, marketing network construction, and upgrade the informationization construction projects, combined with raise about $885 million. 

 

The main business of the pharmaceutical industry is the development, production and sale of the pharmaceutical products. From 2014 to 2016, the operating income of the pharmaceutical industry was 7925.55 million yuan, 10.28 billion yuan and 12.51 billion yuan. Net profit was 3919.87 million yuan, 60.4 million yuan and 136 million yuan respectively. 

 

"Securities journal" reporter noted that this year there have been six medicine medical enterprises IPO application was no, respectively is SAN SAN cfna pharmaceutical, changchun, pharmaceutical, nanjing pharmaceutical co., guangdong baihe medical technology, nott port of health science and technology and medical. 

 

Notable is, because of drug prices many factors, such as pharmaceutical sales link complicated reasons, in financial norm, medicine production enterprises and easy generation of commercial bribery problem between dealers, therefore, the securities and futures commission to dealers and sales link of the financial system has carried on the full attention. 

 

From the point of the medicine and medical enterprise of rejection, three asked about these issues, respectively is chongqing SAN SAN cfna pharmaceutical, nanjing pharmaceutical and zhejiang nott health science and technology. For example, the issuance examination committee of chongqing st cfna pharmaceutical proposed "reimbursement bills are true, legal, compliance, commercial bribery exists or provide convenience for commercial bribery". 

 

The personage inside course of study says, medicine health care industry due to the particularity of its industry, medicine circulation many dealers, complex rules, under the system of the manufacturer and the drug circulation could violate compasses operation, suggested that enterprises should attach importance to the company internal control related situation and system, to avoid problems related to IPO audit is no. 

 

According to the information released by the securities and exchange commission, there are 33 pharmaceutical manufacturers in the IPO queue, including 15 on the Shanghai stock exchange, seven on the shenzhen stock exchange, and 11 on chinext. There are 8 medical enterprises, including 5 Shanghai stock exchange, 2 shenzhen stock market and 1 chinext.